Buy (150 RUB)
|Generate QR code
Open Access
Subscription or Fee Access
Mycoplasma infection and COVID-19 - red flags of diagnosis and treatment
https://doi.org/10.21508/1027-4065-2025-70-1-56-63
Abstract
Respiratory mycoplasmosis and chlamydia in combination with COVID-19 in children during the pandemic is a significant concern in the structure of infectious morbidity.
Objective. The aim of the work is to identify the features of the course of COVID-19 in combination with atypical pathogens.
Materials and methods. The work uses an integrated approach to analyzing data from clinical, laboratory and instrumental examinations in children with a combination of COVID-19 with respiratory mycoplasmosis in comparison with monoinfection groups based on the use of mathematical modeling.
Results. Since the studied groups demonstrated homogeneity in most characteristics, a mathematical model for predicting the risk of combined infections was developed based on the use of a variety of clinical and laboratory data.
Conclusions. Due to the high prevalence of pneumonia in children with a combination of COVID-19 with respiratory mycoplasmosis, the similarity of the key symptoms in comparison with monoinfection, an algorithm for early differential diagnosis of COVID-19 combinations with atypical pathogens has been developed based on the use of mathematical modeling for early identification of these infections at the prehospital stage.
About the Authors
L. N. Mazankovа
Russian Medical Academy of Continuing Professional Education; Bashlyaeva Children’s Municipal Clinical Hospital
Russian Federation
Russian Federation
Moscow
N. A. Dracheva
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Moscow
O. I. Klimova
Russian Medical Academy of Continuing Professional Education
Russian Federation
Russian Federation
Moscow
E. R. Samitova
Russian Medical Academy of Continuing Professional Education; Bashlyaeva Children’s Municipal Clinical Hospital
Russian Federation
Russian Federation
Moscow
References
1. Wu Q., Xing Y., Shi L., Li W., Gao Y., Pan S., et al. Coinfection and Other Clinical Characteristics of COVID-19 in Children. Pediatrics 2020; 146(1): e20200961. DOI: 10.1542/peds.2020
2. Wanga V., Gerdes M.E., Shi D.S., Choudhary R., Dulski T.M., Hsu S., et al. Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 Years Hospitalized with COVID-19 — Six Hospitals, United States, July-August 2021. MMWR Morb Mortal Wkly Rep 2021; 70(5152): 1766–1772. DOI: 10.15585/mmwr.mm705152a3.
3. Götzinger F., Santiago-García B., Noguera-Julián A., Lanaspa M., Lancella L., Calò Carducci F.I., et al. COVID-19 Study Group. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health 2020; 4(9): 653–661. DOI: 10.1016/S2352–4642(20)30177–2
4. Viner R.M., Ward J.L., Hudson L.D., Ashe M., Patel S.V., Hargreaves D., et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch Dis Child 2021; 106(8): 802–807. DOI: 10.1136/archdischild-2020–320972
5. Kim T.Y., Kim J.Y., Shim H.J., Yun S.A., Jang J.H., Huh H.J., et al. Comparison of the PowerChek SARS-CoV-2, Influenza A&B, RSV Multiplex Real-time PCR Kit and BioFire Respiratory Panel 2.1 for simultaneous detection of SARSCoV-2, influenza A and B, and respiratory syncytial virus. J Virol Methods 2021; 298: 114304. DOI: 10.1016/j.jviromet. 2021.114304. Epub 2021 Sep 28.
6. Hoang A., Chorath K., Moreira A., Evans M., Burmeister-Morton F., Burmeister F., et al. COVID-19 in 7780 pediatric patients: A systematic review. EClinicalMedicine 2020; 24: 100433. DOI: 10.1016/j.eclinm.2020.100433
7. Kremplevskaya S.P., Muzyka A.D., Soldatova E.Yu., Pogorelova O.O., Barykin V.I., Mirzonov V.А., et al. Characteristics of and treatment for respiratory mycoplasmosis in children during the epidemic season 2020–2021. Voprosy prakticheskoj pediatrii 2021; 16(3): 37–46. (in Russ.) DOI: 10.20953/1817–7646–2021–3–37–46
8. Korovina N.A., Zaplatnikov A.L. Respiratory mycoplasmosis in children. RMZH 2004; 13: 778. (in Russ.)
9. Gorelov A.V., Kozlov R.S., Andreeva I.V., Geppe N.A., Melekhina E.V., Ryazantsev S.V., et al. Improving the ways of making a medical decision when choosing antibiotic therapy at the outpatient stage for the treatment of respiratory infections in the post-pandemic period. Voprosy prakticheskoj pediatrii 2023; 18(4): 110–122. (in Russ.) DOI: 10.20953/1817–7646–2023–4–110–122
10. Methodological recommendations “features of clinical manifestations and treatment of the disease caused by a new coronavirus infection (COVID-19) in children. Version 2 (07/03/2020). (in Russ.)
11. Osmanov I.M., Alekseeva E.I., Mazankova L.N., Zakharova I.N. et al. Clinical protocol for the treatment of children with new coronavirus infection (COVID-19) undergoing inpatient treatment in medical organizations of the state healthcare system of the city of Moscow. Ed. by A.I. Khripun. M.: NIIOZMM DZM, 2021; 92. (in Russ.)
12. Wu H.Y., Chang P.H., Chen K.Y., Lin I.F., Hsih W.H., Tsai W.L., et al. Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: Incidence, diagnosis and treatment. J Microbiol Immunol Infect 2022; 55(6 Pt 1): 985–992. DOI: 10.1016/j.jmii.2022.09.006
13. Li Y., Wang H., Wang F., Lu X., Du H., Xu J., et al. Co-infections of SARS-CoV-2 with multiple common respiratory pathogens in infected children: A retrospective study. Medicine (Baltimore) 2021; 100(11): e24315. DOI: 10.1097/MD.0000000000024315
14. Pata D., Buonsenso D., Valentini P. Comparison of the Clinical and Laboratory Features of COVID and Influenza in Children. Mediterr J Hematol Infect Dis 2022; 14(1): e2022065. DOI: 10.4084/MJHID.2022.065
Review
For citations:
Mazankovа L.N., Dracheva N.A., Klimova O.I., Samitova E.R. Mycoplasma infection and COVID-19 - red flags of diagnosis and treatment. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2025;70(1):56-63. (In Russ.) https://doi.org/10.21508/1027-4065-2025-70-1-56-63
Views:
187
Email this article 